| Literature DB >> 34342775 |
Anita Adriaantje Harteveld1,2, Annemieke Simone Littooij1,3, Max Maria van Noesel3, Marijn van Stralen1, Clemens Bos4.
Abstract
OBJECTIVES: To examine the feasibility of performing ASL-MRI in paediatric patients with solid abdominal tumours.Entities:
Keywords: Arterial spin labelling (ASL); Magnetic resonance imaging; Neoplasms; Paediatrics; Perfusion
Mesh:
Substances:
Year: 2021 PMID: 34342775 PMCID: PMC8995293 DOI: 10.1007/s10334-021-00943-y
Source DB: PubMed Journal: MAGMA ISSN: 0968-5243 Impact factor: 2.310
Scan parameters
| Parameters | ASL | M0a |
|---|---|---|
| TR/TE [ms] | 4000/21 | 6000/21 |
| EPI-factor | 55 | |
| Flip angle [deg] | 90 | |
| SENSE | 1.5 (RL direction) | |
| FOV [mm2] | 244 × 244 | |
| Acquired voxel size [mm2] | 3 × 3 | |
| Slice thickness [mm] | 6 | |
| Slice gap [mm] | 1 | |
| No. of slices | 9 | |
| Phase encoding direction | RL | |
| Fold-over suppression | Saturation slabsb | |
| Fat-suppression | SPIR | |
| Slice orientation | Coronal | |
| Slice scan order | AP | |
| No. of repetitions | 10c | 4 |
| Labelling duration [s] | 1.5 | N/A |
| Delay time [s] | 0.5, 1.0, 1.5 | N/A |
| Total acquisition time [min:s] | 01:28 (per delay time) | 00:30 |
AP anterior–posterior, ASL arterial spin labelling, EPI echo planar imaging, FH feet–head, FOV field-of-view, SENSE sensitivity encoding, SPIR spectral presaturation with inversion recovery, TE echo time, TR repetition time
aOnly parameter settings that were different from the ASL scan
bSpatial saturation slabs superior and inferior to the image volume to suppress undesired signal aliasing
cLabel-control pairs per delay time
Baseline characteristics of the study population
| Subject | Age (years) | Sex | Primary tumour type | Tumour location | Tumour stage [ | Tumour size | Treatment pre-MRI |
|---|---|---|---|---|---|---|---|
| 1 | 7.8 | F | Neuroblastoma | Left adrenal gland with local and distant (supraclavicular) lymph node metastasis | INSS stage 4 | Primary tumour: 3.8 × 2.3 × 3.1 cm; Lymph node metastases renal hilum: 4.0 × 2.5 × 6.3 cm | 2 × N5/N6, 2 × N8, 2 × MIBG therapy, 2nd line chemotherapy:6 × Bevacizumab and Temozolomide |
| 2 | 8.3 | F | Nephroblastoma | Right kidney (upper pole and lower pole) | Upper pole: local stage I; Lower pole: local stage III (biopsy) | Upper pole: 1.8 × 1.7 × 1.2 cm; Lower pole: 3.0 × 3.9 × 2.5 cm | None. MRI performed at staging |
| 3 | 4.9 | M | Nephroblastoma | Bilateral (largest left kidney) | Left kidney: local stage III; Clinical stage V (bilateral disease with bone metastasis) | Left kidney: 10.0 × 7.4 × 7.6 cm | 8 week pre-operative treatment 3 drugs: VCR/ACT/DOX |
| 4 | 1.7 | M | Neuroblastoma | Left adrenal gland with local and distant (supraclavicular) lymph node metastases | INSS stage 4 | 5.8 × 3.6 × 6.3 cm | 3 × N5/N6 |
| 5 | 2.7 | F | Nephroblastoma | Right kidney | Local stage II | 7.4 × 6.1 × 6.0 cm | 4 week chemo (VCR/ACT) |
| 6 | 3.3 | F | Nephroblastoma | Right kidney | Local stage I | 7.3 × 6.9 × 6.4 cm | 4 week chemo (VCR/ACT) |
| 7 | 4.1 | F | Neuroblastoma | Left adrenal gland with liver, bone marrow and lymph node metastases | INSS stage 4 | 10.9 × 8.8 × 8.5 cm | None. MRI performed at staging |
| 8 | 3.8 | M | Neuroblastoma | Right adrenal gland | INSS stage 3 | 12.7 × 10.8 × 11.2 cm | None. MRI performed at staging |
| 9 | 2.2 | F | Nephroblastoma | Right kidney | Local stage I | 8.5 × 7.7 × 8.3 cm | 4 week chemo (VCR/ACT) |
| 10 | 4.1 | M | Nephroblastoma | Right kidney | Local stage I | 6.8 × 4.7 × 4.6 cm | None. MRI performed at staging |
ACT actinomycin, DOX doxorubicin, INSS International Neuroblastoma Staging System, MIBG meta-iodobenzyl guanidine, N5 cisplatin, etoposide and vindesine, N6 vincristine, dacarbacine, ifosfamide and doxorubicin, N8 topotecan, cyclophosphamide and etoposide, VCR vincristine
Fig. 1Example of motion correction results of images cropped around the tumour and contralateral left kidney (subject 8 in Table 2). Images visualise the same intersection (yellow line in the coronal image) over all M0 and raw ASL images. Improved alignment can be observed after image registration, for instance by looking at voxels representing the edges of the tumour/kidney
Fig. 2A 7-year-old female patient diagnosed with a neuroblastoma in the left adrenal gland (subject 1 in Table 2). Processed ASL and M0 images are shown cropped around the tumour (upper row) and right kidney (bottom row), together with the reformatted T2w and T1w-subtracted images that were used for analysis of the tumour. The anatomical location of the neuroblastoma can be appreciated on the coronal T2w images (arrow). The graph on the right shows the perfusion-weighted signal (PWS) as a function of post-labelling delay (PLD) resulting from the ROI analysis. Green contours: whole-tumour and kidney regions that were used for the ROI analysis; yellow ROI (overlayed on M0 image tumour): tumour region with contrast enhancement on the T1w-subtracted image. Colour scale bar indicates PWS (∆M/M0 × 100%). PLD1 = 0.5 s; PLD2 = 1.0 s; PLD3 = 1.5 s
Fig. 3A 4-year-old male patient diagnosed with a bilateral nephroblastoma (subject 3 in Table 2). Processed ASL and M0 images are shown cropped around the tumour (upper row) and right kidney (bottom row), together with the reformatted T2w and T1w-subtracted images that were used for analysis of the tumour. The anatomical location of the nephroblastoma can be appreciated on the coronal T2w images (arrow indicates the largest tumour that was used for analysis). The graph on the right shows the perfusion-weighted signal (PWS) as a function of post-labelling delay (PLD) resulting from the ROI analysis. Green contours: whole-tumour and kidney regions that were used for the ROI analysis; yellow ROI (overlayed on M0 image tumour): tumour region with contrast enhancement on the T1w-subtracted image; red ROI (overlayed on M0 image tumour): tumour region without contrast enhancement on the T1w-subtracted image. Colour scale bar indicates PWS (∆M/M0 × 100%). PLD1 = 0.5 s; PLD2 = 1.0 s; PLD3 = 1.5 s
ROI sizes used in the analysis for each tissue type
| ROI | Number of voxels | ||
|---|---|---|---|
| Mean | Minimum | Maximum | |
| Whole-tumour | 3568 | 231 | 9476 |
| Contralateral kidney | 1015 | 435 | 1575 |
| Non-enhancing tumour | 617 | 3 | 2422 |
| Enhancing tumour | 896 | 31 | 3718 |
Fig. 4a, b Example cases from two patients (subject 2 and 9 in Table 2) showing high PWS inside the tumour on PWS images obtained with the shortest PLD of 0.5 s (PLD1) that coincided with local hypo-intense areas on the reformatted T2w images (white arrow heads). c This case (subject 8 in Table 2) shows very well the high PWS of labelled blood flowing inside the larger arteries (descending aorta and right renal artery; white arrow heads) indicating successful labelling. Many of the small regions with high PWS inside the tumour corresponded with hypo-intense regions on the T2w images, however, due to blurring effects after reformatting of the T2w image to the geometry of the ASL images these hypo-intense areas could not be visualised clearly here. The green contours indicate the tumour region. Colour scale bar indicates PWS (∆M/M0 × 100%)
Fig. 5ROI analysis of PWS values obtained from pCASL images within the whole-tumour and contralateral kidney regions in 10 paediatric patients diagnosed with neuroblastoma (black) or nephroblastoma (red). The PWS measured in the kidney shows the method is sensitive to perfusion. Data points represent the average PWS in the whole-tumour region (left) and contralateral kidney region (right) at each delay time. The error bars represent the 95% confidence interval. For clarity data points are slightly shifted with respect to each other at each post-labelling delay and one-sided error bars are shown. pCASL pseudo-continuous arterial spin labelling, PWS perfusion weighted signal
Fig. 6ROI analysis of PWS values obtained from pCASL images within non-enhancing and enhancing subregions of the tumour in 10 paediatric patients diagnosed with neuroblastoma (black) or nephroblastoma (red). Data points represent the average PWS in non-enhancing (left) and enhancing tumour regions (right) at each delay time. A minority of two neuroblastoma cases show increased PWS in enhancing regions inside the tumour. One of the neuroblastoma patients is missing a data point (post-labelling delay 1500 ms), since this scan was accidentally omitted during acquisition. The error bars represent the 95% confidence interval. For clarity data points are slightly shifted with respect to each other at each post-labelling delay and one-sided error bars are shown. pCASL pseudo-continuous arterial spin labelling, PWS perfusion weighted signal